CPORT-E: Comparison of percutaneous treatment cost in hospitals with and without central vascular surgery.

A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed for 9 months and the costs were evaluated. Mortality and the occurrence of events were not different between the two groups. The cost of treatment was lower in the central vascular surgery centers (23,961 USD versus 25,540 USD, p = 0.02).

Conclusion: Coronary angioplasty in hospitals with central vascular surgery reduces costs.

Comment: The cost difference is probably related to the standby surgery centers having a greater volume and therefore more experience than smaller centers without surgery

2_eric_eisenstein
Eric Eisenstein
2012-11-04

Original title: Economic Outcomes of Percutaneous Coronary Intervention Performed at Sites With and Without On-Site Cardiac Surgery.

 

More articles by this author

TACT trial: Chelation Therapy for the Treatment of Coronary Disease.

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol...

TRILOGY Trial: First large scale test evaluating platelet function in acute coronary syndromes.

TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel...

FREEDOM trial: CABG versus angioplasty treatment for diabetic patients with multivessel disease

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at...

Artic Study: Bedside Platelet Function Monitoring to Reduce Events after DES Implantation .

Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial. The ARTIC study tested the superiority...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transapical TMVR in High Risk Patients: Intrepid 5-Year Outcomes

Moderate to severe mitral valve regurgitation (MR) continues is still a high prevalence condition with bad prognosis, particularly among the elderly with left ventricular...

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....